1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
Original Article
You have full text access to this OnlineOpen article
Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice
Article first published online: 14 DEC 2006
DOI: 10.1097/00054725-200501000-00005
Copyright © 2005 Crohn's & Colitis Foundation of America, Inc.
1536-4844/asset/cover.gif?v=1&s=25b2a9cf29f51ddb99420e9a71bd898bfa57a8a9 "Inflammatory Bowel Diseases")
Additional Information
How to Cite
Ueno, Y., Tanaka, S., Sumii, M., Miyake, S., Tazuma, S., Taniguchi, M., Yamamura, T. and Chayama, K. (2005), Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice. Inflamm Bowel Dis, 11: 35–41. doi: 10.1097/00054725-200501000-00005
Publication History
- Issue published online: 14 DEC 2006
- Article first published online: 14 DEC 2006
- Manuscript Accepted: 20 SEP 2004
- Manuscript Received: 25 MAR 2004
Funded by
- Organization for Pharmaceutical Safety and Research
References
- 1, , , et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003; 21: 483–513.
- 2, . Janus-like role of regulatory iNKT cells in autoimmune disease and tumor immunity. Nat Rev Immunol. 2003; 3: 211–222.
- 3, , , et al. NKT cell subsets in infection and inflammation. Immunol Lett. 2003; 85: 159–163.
- 4, . Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr Pharm Des. 2003; 9: 201–220.
- 5, . Invariant Vα14 NKT lymphocytes: a double-edged immuno-regulatory T cell population. Eur Cytokine Netw. 2003; 14: 4–14.
- 6, , . Tissue-specific recognition of mouse CD1 molecules. J Immunol. 1998; 160: 3128–3134.
- 7, , , et al. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol Immunol. 1998; 35: 525–536.
- 8, , , et al. The multiple roles of major histocompatibility complex class-I-like molecules in mucosal immune function. Acta Odontol Scand. 2001; 59: 139–144.
- 9, , , et al. CD1d-restricted T cell pathways at the epithelial-lymphocyte-luminal interface. J Pediatr Gastroenterol Nutr. 2004; 39: S719–S722.
- 10, . Rat T-cell receptor TRAV11 (Vα14) genes: further evidence of extensive multiplicity with homogeneous CDR1 and diversified CDR2 by genomic contig and cDNA analysis. Immunogenetics. 2004; 55: 756–762.
- 11, , . Agelasphins, novel α-galactosylceramides from marine sponge Agelas mauritianus. Tetrahedron Lett. 1993; 34: 5591–5592.
- 12, , , et al. Agelasphins, novel antitumor and immunostimulatory cerebrosides from marine sponge Agelas mauritianus. Tetrahedron. 1994; 50: 2771–2784.
- 13, , , et al. CD1d-restricted and TCR-mediated activation of V alpha 14 NKT cells by glycosylceramides. Science. 1997; 278: 1626–1629.
- 14, , , et al. Selective ability of mouse CD1 to present glycolipids: α-galactosylceramide specifically stimulates Vα14+ NKT lymphocytes. J Immunol. 1998; 161: 3271–3281.
- 15, , , et al. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol. 1996; 26: 2989–2998.
- 16, , , et al. α/β-T cell receptor (TCR)+ CD4−CD8−(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med. 1998; 187: 1047–1056.
- 17, , , et al. Selective reduction of Vα14+ NKT cells associated with disease development in autoimmune-prone mice. J Immunol. 1996; 156: 4035–4040.
- 18, , , et al. Extreme Th1 bias of invariant Vα24JαQ T cells in type-I diabetes. Nature. 1998; 391: 177–181.
- 19, , , et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997; 278: 1623–1626.
- 20, , , et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci USA. 1998; 95: 5690–5693.
- 21, , , et al. Liver NK1.1+CD4+αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol. 1996; 156: 3366–3373.
- 22, , , et al. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol. 1999; 163: 2387–2391.
- 23, , . Interferon γ production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J Exp Med. 1996; 183: 2391–2396.
- 24, . Cultured NK1.1+CD4+ T cells produce large amounts of IL-4 and IFN-γ upon activation by anti-CD3 or CD1. J Immunol. 1997; 159: 2240–2249.
- 25, , . Bacille Calmette Guerin and interleukin-12 down-modulate interleukin-4 producing CD4+NK1+T lymphocytes. Eur J Immunol. 1997; 27: 183–188.
- 26, , , et al. IL-4 producing NK T cells are biased towards IFN-γ production by IL-12. Influence of the microenvironment on the functional capacities of NKT cells. Eur J Immunol. 1998; 28: 1507–1515.
- 27, , , et al. NK1.1+T cells from interleukin-7 deficient mice have a normal distribution and selection but exhibit impaired cytokine productioin. Int Immunol. 1996; 8: 1759–1766.
- 28, , , et al. Requirement of IL-7 for IL-4-producing potential of MHC class I-selected CD4−CD8−TCαβ+ thymocytes. Int Immunol. 1997; 9: 73–79.
- 29, , , et al. IL-4-producing NK1.1+T cells are resistant to glucocorticoid-induced apoptosis: implications for the Th1/Th2 balance. J Immunol. 1998; 161: 1239–1247.
- 30, , , et al. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NKT cells. J Immunol. 2001; 166: 662–668.
- 31, , . A Synthetic glicolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 2001; 413: 531–534.
- 32, , , et al. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology. 2000; 119: 119–128.
- 33, , , et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002; 17: 629–638.
- 34, , . Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim. 2000; 49: 9–15.
- 35, , , et al. A synthetic mimetic CD4 is able to suppress disease in a rodent model of immune colitis. Eur J Immunol. 1999; 29: 355–366.
- 36, , , et al. 2001. IL-1β-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA. 2001; 98: 13249–13254.
- 37, , , et al. Regulation of mucosal immune responses by recombinant interleukin 10 produced by intestinal epithelial cells in mice. Gastroenterology. 2002; 122: 1829–1841.
- 38, , , et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol. 2000; 164: 6303–6312.
- 39, , , et al. Interferon-γ and tumor necrosis factor-induced nitric oxide as toxic effector molecule in chronic dextran sulfate sodium-induced colitis in mice. Clin Exp Immunol. 1999; 116: 238–245.
- 40, , , et al. Dextran sulphate sodium-induced colitis is ameliorated in interleukin 4 deficient mice. Genes Immun. 2001; 2: 309–316.
- 41, , , et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000; 289: 1352–1355.
- 42, , , et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002; 16: 219–230.
- 43, , , et al. Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci USA. 1999; 96: 13938–13943.
- 44, . Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002; 23: 445–449.
- 45, , , et al. CD1-dependent dendritic cell instruction. Nat Immunol. 2002; 3: 1163–1168.
- 46, , , et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999; 189: 1121–1128.
- 47, , . Understanding the function of CD1-restricted T cells. Nat Immunol. 2003; 4: 517–523.
- 48, , , et al. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur J Immunol. 2003; 33: 1073–1083.
- 49, , , et al. Activation of Vα14+ natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun. 2001; 69: 213–220.
- 50, , , et al. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA. 2000; 97: 8461–8466.
- 51, , . Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol. 1999; 29: 2014–2025.
- 52, , , et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001; 7: 1052–1056.
- 53, , , et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type I diabetes. Nat Med. 2001; 7: 1057–1062.
- 54, , , et al. Nonclassical CD1d-restricted NKT cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004; 113: 1490–1497.
- 55. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417–429.